Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
8.6
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2023年4月1日〜2023年6月30日ConsolidatedIFRSNet Sales37,012¥ millionYear on year +3.9%Progress 25.5%
Operating profit11,163¥ millionYear on year +8.6%Progress 34.9%
Ordinary income11,440¥ millionYear on year +8.8%Progress 35.2%
Net income attributable to owners of the parent8,749¥ millionYear on year +6.1%Progress 35.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share129.91円
Financial position at period-end
Total assets237,408¥ million
of which net assets 202,799 ¥ millionEquity ratio 85.3%vs. prior year-end +2.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+526
Investment-2,060
Financials-4,047
Net change-5,581
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥55,251 million
Segment revenue
Pharmaceuticals Business30,87083.4%+1.5%
Functional Foods Business6,14216.6%+17.9%
Segment profit
Pharmaceuticals Business10,30397.1%
Functional Foods Business3042.9%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥145,000 million (YoY +0.5%)
Operating profit¥32,000 million (YoY +6.5%)
Ordinary income¥32,500 million (YoY +6.6%)
Net income¥25,000 million (YoY +9.6%)
Annual Dividend Forecast¥114 → ¥120（+5.3%）
Factors Behind Changes in Business Performance
増収と売上構成による売上原価率の低下等。医薬品事業ではビルテプソ、ウプトラビ、海外売上に伴うロイヤリティ収入等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Depreciation and amortization¥1,236 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results Briefing有（機関投資家・証券アナリスト向けカンファレンスコール）
Issued Shares at Period-End70,251,484
Treasury Shares at Period-End2,898,645
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年4月1日〜2023年6月30日 |
| Net Sales | ¥37,012 million (YoY +3.9%) |
| Operating profit | ¥11,163 million (YoY +8.6%) |
| Ordinary income | ¥11,440 million (YoY +8.8%) |
| Profit attributable to owners of the parent | ¥8,749 million (YoY +6.1%) |
| Net income per share | 129.91円 |
| Equity ratio | End of the current fiscal period 85.3 / End of previous period 82.4 |
| Total assets | ¥237,408 million |
| Net assets | ¥202,799 million |
| Cash flows from operating activities | ¥526 million |
| Cash flows from investing activities | ¥-2,060 million |
| Cash flows from financing activities | ¥-4,047 million |
| Cash and cash equivalents at end of period | ¥55,251 million |
| Full-year earnings forecast | Net Sales ¥145,000 million (YoY +0.5%) / Operating profit ¥32,000 million (YoY +6.5%) / Ordinary income ¥32,500 million (YoY +6.6%) / Net income ¥25,000 million (YoY +9.6%) |
| Annual Dividend Forecast | ¥114 → ¥120（+5.3%） |
| Segment revenue | Pharmaceuticals Business ¥30,870 million (YoY +1.5%) / Functional Foods Business ¥6,142 million (YoY +17.9%) |
| Segment profit | Pharmaceuticals Business ¥10,303 million / Functional Foods Business ¥304 million |
| Depreciation and amortization | ¥1,236 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | 有（機関投資家・証券アナリスト向けカンファレンスコール） |
| Issued Shares at Period-End | 70,251,484 |
| Treasury Shares at Period-End | 2,898,645 |
| Factors Behind Changes in Business Performance | 増収と売上構成による売上原価率の低下等。医薬品事業ではビルテプソ、ウプトラビ、海外売上に伴うロイヤリティ収入等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加。 |
Items this document does not state (9)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.増収と、売上構成による売上原価率の低下等により営業利益が増加した。医薬品事業ではビルテプソ、ウプトラビ、海外売上に伴うロイヤリティ収入等が伸長し、機能食品事業ではプロテイン製剤やサプリメント等の売上が増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.